Dianwen Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dianwen Song has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Lin Li
Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, China
4 shared publicationsFeiran Gao
Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, International Campus, Zhejiang University, Haining, China
3 shared publications- Jian Liu
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China
3 shared publications Jinjin Xu
Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China
3 shared publicationsJishuai Zhang
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of lifeomics, Beijing, China
3 shared publicationsLei Ji
Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2793
Editorial Expression of Concern: Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2793
Open AccessEditorial Expression of Concern: Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
- Open Access
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
SMAD4 is mutated in human lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generate a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and Smad4 fl/fl LOF mutations (SPK), showing a much higher incidence of tumor metastases than the Kras G12D , p53 fl/fl (PK) mice. Molecularly, PAK3 is identified as a downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice is achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3′UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components is observed in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
- 11 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Open AccessLoss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
SMAD4 is mutated in human lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generate a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and Smad4 fl/fl LOF mutations (SPK), showing a much higher incidence of tumor metastases than the Kras G12D , p53 fl/fl (PK) mice. Molecularly, PAK3 is identified as a downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice is achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3′UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components is observed in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
- Open Access
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
Over 85% of lung cancer patients harbor overt or subclinical metastases at diagnosis, and therefore most patients die of progressive metastatic disease despite aggressive local and systemic therapies. Somatic mutations in the Smad4 gene have been found in non-small-cell lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generated a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and/or Smad4 fl/fl LOF mutations. The Smad4 fl/fl ; p53 fl/fl ; Kras G12D (SPK) mutant mice manifested a much higher incidence of tumor metastases than the p53 fl/fl ; Kras G12D (PK) mice. Molecularly, PAK3 was identified as a novel downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice was achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3’UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components suggests clinical use of Smad4 LOF as a potential marker for prognosis in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
Open AccessLoss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation
Over 85% of lung cancer patients harbor overt or subclinical metastases at diagnosis, and therefore most patients die of progressive metastatic disease despite aggressive local and systemic therapies. Somatic mutations in the Smad4 gene have been found in non-small-cell lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generated a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and/or Smad4 fl/fl LOF mutations. The Smad4 fl/fl ; p53 fl/fl ; Kras G12D (SPK) mutant mice manifested a much higher incidence of tumor metastases than the p53 fl/fl ; Kras G12D (PK) mice. Molecularly, PAK3 was identified as a novel downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice was achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3’UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components suggests clinical use of Smad4 LOF as a potential marker for prognosis in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.
- Open Access
- 5 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (20) , 33644-33651
FOXD3 regulates anaplastic thyroid cancer progression
FOXD3 regulates anaplastic thyroid cancer progression FOXD3 regulates anaplastic thyroid cancer progression
- 5 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (20) , 33644-33651
Open AccessFOXD3 regulates anaplastic thyroid cancer progression
FOXD3 regulates anaplastic thyroid cancer progression FOXD3 regulates anaplastic thyroid cancer progression
- Open Access
- 24 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (13) , 21884-21891
SPC24 is critical for anaplastic thyroid cancer progression
SPC24 is critical for anaplastic thyroid cancer progression
- 24 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (13) , 21884-21891
Open AccessSPC24 is critical for anaplastic thyroid cancer progression
SPC24 is critical for anaplastic thyroid cancer progression